Navigation Links
Takeda Responds to U.S. Food and Drug Administration Update to Safety Review of ACTOS (pioglitazone HCl)
Date:6/15/2011

DEERFIELD, Ill., June 15, 2011 /PRNewswire/ -- Following an announcement today from the U.S. Food and Drug Administration (FDA) regarding an update to its safety review of ACTOS, Takeda Pharmaceuticals North America, Inc. (Takeda) is confident in the therapeutic benefits of ACTOS and its importance as a treatment for type 2 diabetes. The company remains committed to ACTOS and ACTOS-containing medications, and to the millions of people living with the disease.

Takeda is dedicated to patient safety, and to ensuring that patients and physicians have accurate information regarding ACTOS. Takeda is committed to ongoing clinical research to understand and investigate potential safety concerns, and, working with appropriate regulatory agencies, is currently supporting a ten-year epidemiological study, started in 2002 by the University of Pennsylvania (U. of Penn.) and Kaiser Permanente Diabetes Registry, Northern California (KPNC), investigating the questions raised about ACTOS and bladder cancer. Takeda has been working with the FDA and European Medicines Agency (EMA) and has provided them with interim data from this study on a regular basis. Takeda is committed to supporting this study through its conclusion at the end of 2012 and will report on the final results upon completion.  

In the interim analysis of this epidemiologic data, published in Diabetes Care April 2011, the primary endpoint showed that treatment with ACTOS was not associated with a statistically significant increase in the incidence of bladder cancer. The investigators reported that "short-term use of pioglitazone was not associated with an increased incidence of bladder cancer, but use for more than two years was weakly associated with increased risk."  

Based on its recent data review, FDA has informed the public that "...use of the diabetes medication ACTOS (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer."  Takeda is working with FDA to make appropriate updates to the prescribing information.

Takeda encourages patients with questions to speak with their health care providers. Takeda has consistently emphasized the importance of physician education and patient safety in communications involving ACTOS, and has prioritized communicating the appropriate use of ACTOS in patients with type 2 diabetes.

ACTOS has been an effective and appropriate treatment option, along with diet and exercise, to improve blood sugar (glucose) control for many people living with type 2 diabetes and has been prescribed for more than 10 million patients to date. Since its launch, more than 100 million ACTOS prescriptions have been written globally.

About ACTOS (pioglitazone HCl) Indications and Usage

ACTOS (pioglitazone HCl) is a prescription medication used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes. ACTOS is not for patients with type 1 "juvenile" diabetes or diabetic ketoacidosis.

Important Safety Information

Warning: Heart Failure

ACTOS is not for everyone. ACTOS can cause or worsen heart failure. Heart failure means that the heart does not pump blood well enough. Patients should talk to their doctor immediately if they experience unusually fast weight gain, fluid retention (swelling), shortness of breath, or unusual tiredness. Certain patients with symptoms of heart failure should not start taking ACTOS. Patients should not take ACTOS if they have severe heart failure.

Patients should not take ACTOS if they are allergic to any of its ingredients.

ACTOS may cause liver problems. Patients should talk to their doctor immediately if they experience unexplained nausea, vomiting, stomach pain, unusual tiredness, loss of appetite, dark urine, or yellowing of the skin or eyes as these could be symptoms of liver damage.

Women are at higher risk of having broken bones (fractures) while taking ACTOS.

When taking ACTOS with insulin or other anti-diabetic medications (especially sulfonylureas), hypoglycemia may occur. Lightheadedness, shakiness, dizziness, or hunger may mean that a patient's blood sugar is too low. Patients should talk to their doctor if low blood sugar is a problem for them.

Some patients have experienced visual changes while taking ACTOS. If patients experience vision problems, they should consult their doctor immediately. Patients should have their eyes checked regularly.

If a patient is of childbearing age, but does not have regular monthly periods, she should talk to her doctor before taking ACTOS, as it could increase her chances of becoming pregnant.

The most common side effects of ACTOS include cold-like symptoms, headache, sinus infection, muscle pain, and sore throat.

Patients should tell their doctor about all the medicines, vitamins, and supplements they take. ACTOS and some other medicines can affect each other. Patients may need to have their doses of ACTOS or certain other medicines changed.

It is not known if ACTOS can harm an unborn, or nursing, baby. A patient should talk to her doctor if she is pregnant, planning to become pregnant, breastfeeding, or planning to breastfeed.

Individuals are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For complete prescribing information, including warning about heart failure, and Medication Guide, please visit www.ACTOS.com.

Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc.

Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc. are subsidiaries of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. The respective companies currently market oral diabetes, insomnia, rheumatology, gastroenterology, and cardiovascular treatments and seek to bring innovative products to patients through a pipeline that includes compounds in development for metabolic and cardiovascular disease, gastroenterology, neurology and other conditions. To learn more about these Takeda companies, visit www.tpna.com.


'/>"/>
SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Takeda to Acquire Nycomed
2. Amylin and Takeda Voluntarily Suspend Clinical Activities in Obesity Trial
3. Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
4. Handa Pharmaceuticals Announces Submission of Its First-to-File ANDA for Takedas DEXILANT®
5. Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension
6. Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles
7. Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride)
8. Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S.
9. Arthritis Foundation and Takeda Launch First-Ever National Gout Public Service Announcement (PSA) Campaign, Urging People Living With Gout to Keep Enjoying Lifes Simple Pleasures
10. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
11. Takeda Responds to FDA Advisory Committee Recommendation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... PUNE, India , May 27, 2016 ... in the instances of hypertension is driving ambulatory blood ... muscles lose their elasticity and their ability to respond ... blood pressure. This condition can lead to various cardiovascular ... and peripheral vascular disease. These diseases are growing in ...
(Date:5/26/2016)... , May 26, 2016 According ... "Medical Waste Management Market - U.S. Industry Analysis, Size, Share, ... management market in the U.S. was valued at US$ 5.89 ... CAGR of 3.4% from 2015 to 2023 to reach US$ ... analysis of current and emerging needle free drug delivery devices ...
(Date:5/25/2016)... May 25,2016 FDA 510(k) ... Cellvizio platform for urological and surgical applications ... inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... in the US with the 12 th ... Administration (FDA). This new FDA clearance covers Confocal ...
Breaking Medicine Technology:
(Date:5/28/2016)... ... 2016 , ... After a year and a half of planning the Multiple Pathways of ... Multiple Pathways of Recovery Conference was held May 2 -4, 2016 at the Mystic ... came together to explore the many pathways individuals use to get into and sustain their ...
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of Horizon Blue Cross Blue ... Industry (TWIN) 2016 honorees. The award recognizes businesswomen who excel in their fields ... Director of the MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ Health ...
(Date:5/27/2016)... ... , ... This campaign aims to provide a path to improved education and ... and change. , As nearly 795,000 Americans suffering from a new or recurrent stoke ... with an estimated 129,000 of these people dying from stroke, it’s become our nation’s ...
(Date:5/27/2016)... ... 27, 2016 , ... Aimed at nurses and employees in ... courtesy of leaders in the nursing and health care industry. It also provides ... and associations—namely Jones & Bartlett Learning. , Jones & Bartlett Learning is adding ...
(Date:5/26/2016)... ... ... Despite last week’s media reports hinting at a June rate hike after the ... for an interest rate increase, according to Rajeev Dhawan of the Economic Forecasting Center ... Market Committee (FOMC) dot charts are of interest to the press for their noise ...
Breaking Medicine News(10 mins):